Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre
Diseases · 18.11.2026 · 14 (11) · 427
DOI: 10.3390/diseases14110427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases, online erschienen am 18.11.2026. Verfasst von Francesco Rocco Bertuccio und 10 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hospitalised exacerbations of non-cystic fibrosis bronchiectasis are clinically heterogeneous, yet inpatient microbiology and management remain incompletely characterised.
Methods
We retrospectively analysed 53 consecutive hospitalisations in 47 adults (2023–2024), describing respiratory severity, microbiological findings, antimicrobial exposure, corticosteroid use and length of stay (LOS), without a comparator group.
Results
Acute respiratory failure was documented in 12/53 episodes (22.6%), and Pseudomonas aeruginosa was isolated in 19/53 (35.8%). An exploratory four-domain classification (bacteria, nontuberculous mycobacteria, fungi and viruses), incorporating historical and acute findings, identified ≥2 domains in 24/53 episodes (45.3%); median LOS was 18.5 versus 15 days for ≥2 versus 0–1 domains. Intravenous antibacterials were recorded in 51/53 episodes (96.2%) and inhaled amikacin in 28/53 (52.8%). Median systemic antibacterial treatment duration, calculated from recorded concurrent antibiotic courses, was 11 days during hospitalisation and 11.5 days including documented pretreatment. Systemic corticosteroids were recorded in 28/53 episodes (52.8%), including 15/30 without documented COPD or asthma. Overall median LOS was 16 days (IQR 12–20), with one in-hospital death (1.9%).
Conclusions
Hospitalised exacerbations involved heterogeneous microbiological findings and frequent acute inhaled antibiotic and systemic corticosteroid use. The overlap–LOS contrast is descriptive, not prognostic, and reconstructed durations cannot establish treatment appropriateness. Prospective studies should assess prescribing indications, microbiological context and clinical response.
Zitieren
APA
Bertuccio, F. R., Pisanu, L., Arminio, M., Arlando, L., Tafa, M., Reposi, P. C., Gallo, E., Corsico, A. G., Cascina, A., Conio, V., & Stella, G. M. (2026). Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre. Diseases, 14(11), 427. https://doi.org/10.3390/diseases14110427
Vancouver
Bertuccio FR, Pisanu L, Arminio M, Arlando L, Tafa M, Reposi PC, et al. Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre. Diseases. 2026;14(11):427. doi:10.3390/diseases14110427
BibTeX
@article{Bertuccio2026,
author = {Bertuccio, Francesco Rocco and Pisanu, Lucrezia and Arminio, Maria and Arlando, Lorenzo and Tafa, Mitela and Reposi, Paolo Cosseta and Gallo, Elisabetta and Corsico, Angelo Guido and Cascina, Alessandro and Conio, Valentina and Stella, Giulia Maria},
title = {Severe Exacerbations of Non-Cystic Fibrosis Bronchiectasis Requiring Hospitalisation: Microbiology and Inpatient Management in a Tertiary Care Centre},
journal = {Diseases},
year = {2026},
volume = {14},
number = {11},
pages = {427},
doi = {10.3390/diseases14110427}
}
EUVIMED